Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers
- PMID: 30423193
- DOI: 10.1002/cncr.31833
Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers
Abstract
Background: Among men with localized high-risk prostate cancer (PCa), patients who meet very high-risk (VHR) criteria have been shown to experience worse outcomes after radical prostatectomy (RP) in a previous study. Variations of VHR criteria have been suggested to be prognostic in other single-center cohorts, but multicenter outcomes validating VHR criteria have not been described. This study was designed to validate VHR criteria for identifying which PCa patients are at greatest risk for cancer progression.
Methods: Patients with high-risk PCa undergoing RP (2005-2015) at 3 tertiary centers were pooled. The outcomes of men with VHR PCa were compared with the outcomes of those who did not meet VHR criteria. The high-risk criteria were a clinical stage of T3 to T4, a prostate-specific antigen level > 20 ng/mL, or a biopsy Gleason grade sum of 8 to 10. The VHR criteria were multiple high-risk features, >4 biopsy cores with a Gleason grade sum of 8 to 10, or primary Gleason grade pattern 5. Biochemical recurrence, metastasis (METS), and cancer-specific mortality (CSM) were assessed with competing risks regressions. Overall mortality was assessed with Cox survival models.
Results: Among 1981 patients with high-risk PCa, men with VHR PCa (n = 602) had adverse pathologic outcomes: 37% versus 25% for positive margins and 37% versus 15% for positive lymph nodes (P < .001 for both comparisons). Patients with VHR PCa also had higher adjusted hazard ratios for METS (2.78; 95% confidence interval [CI], 2.08-3.72), CSM (6.77; 95% CI, 2.91-15.7), and overall mortality (2.44; 95% CI, 1.56-3.80; P < .001 for all comparisons).
Conclusions: In a validation study of patients who underwent treatment for high-risk PCa, VHR criteria were strongly associated with adverse pathologic and oncologic outcomes.
Keywords: cancer-specific mortality; high-risk localized prostate cancer; metastasis; prostate cancer; risk stratification.
© 2018 American Cancer Society.
Similar articles
-
Very-high-risk localized prostate cancer: definition and outcomes.Prostate Cancer Prostatic Dis. 2014 Mar;17(1):57-63. doi: 10.1038/pcan.2013.46. Epub 2013 Nov 5. Prostate Cancer Prostatic Dis. 2014. PMID: 24189998 Free PMC article.
-
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.Eur Urol. 2016 Jun;69(6):1142-8. doi: 10.1016/j.eururo.2015.12.010. Epub 2015 Dec 31. Eur Urol. 2016. PMID: 26749093
-
Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.Eur Urol. 2014 Dec;66(6):1116-24. doi: 10.1016/j.eururo.2014.07.004. Epub 2014 Jul 19. Eur Urol. 2014. PMID: 25052213
-
Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review.World J Urol. 2021 Nov;39(11):4085-4099. doi: 10.1007/s00345-021-03703-8. Epub 2021 May 28. World J Urol. 2021. PMID: 34047825 Free PMC article.
-
Impact of biopsy perineural invasion on the outcomes of patients who underwent radical prostatectomy: a systematic review and meta-analysis.Scand J Urol. 2019 Oct;53(5):287-294. doi: 10.1080/21681805.2019.1643913. Epub 2019 Aug 10. Scand J Urol. 2019. PMID: 31401922
Cited by
-
Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial.Trials. 2021 Oct 21;22(1):728. doi: 10.1186/s13063-021-05708-5. Trials. 2021. PMID: 34674739 Free PMC article.
-
Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical Prostatectomy.JCO Precis Oncol. 2019;3:PO.19.00081. doi: 10.1200/PO.19.00081. Epub 2019 Jul 26. JCO Precis Oncol. 2019. PMID: 31650100 Free PMC article.
-
Very-high-risk (VHR) localized prostate cancer: an indication for multimodal therapy.Oncotarget. 2019 Mar 8;10(20):1870-1871. doi: 10.18632/oncotarget.26757. eCollection 2019 Mar 8. Oncotarget. 2019. PMID: 30956769 Free PMC article. No abstract available.
-
The prognostic significance of the clinical T stage and Grade Group in patients with locally advanced prostate cancer treated via high-dose-rate brachytherapy and external beam radiation.Int J Clin Oncol. 2023 Aug;28(8):1092-1100. doi: 10.1007/s10147-023-02359-1. Epub 2023 May 25. Int J Clin Oncol. 2023. PMID: 37227547
-
Identification of Enzalutamide Resistance-Related circRNA-miRNA-mRNA Regulatory Networks in Patients with Prostate Cancer.Onco Targets Ther. 2021 Jun 21;14:3833-3848. doi: 10.2147/OTT.S309917. eCollection 2021. Onco Targets Ther. 2021. Retraction in: Onco Targets Ther. 2023 Jul 18;16:583-584. doi: 10.2147/OTT.S430430. PMID: 34188491 Free PMC article. Retracted.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials